Director, Dmpk

Valo Health is a technology company that is integrating human-centric data and AI-powered technology to accelerate the creation of life-changing drugs for more patients faster. Valo was created with the belief that the drug discovery and development process can and should be faster and less expensive, with a much higher probability of success. We are using models early to fail less often, executing clinical trials to add valuation to the company, and generating fit-for-purpose data to feed back into Valo's Opal Computational Platform as we reinvent drug discovery and development from the ground up. Disease doesn't wait, so neither can we.

We are a multi-disciplinary team of experts in science, technology, and pharmaceuticals united in our mission to achieve better drugs for patients faster. Valo is committed to hiring diverse talent, prioritizing growth and development, fostering an inclusive environment, and creating opportunities to bring together a group of different experiences, backgrounds, and voices to work together. We achieve the widest-ranging impact when we leverage our broad backgrounds and perspectives to accelerate a new frontier in health. Valo seeks to become the catalyst for the pharmaceutical industry and drive the digital transformation of the industry. Are you ready to join us?

The Director/Senior Director, DMPK will set strategy and lead activities associated with design, management, analysis, and interpretation of in vitro and in vivo experiments of absorption, distribution, metabolism, and elimination for Valo's internal cardiovascular indication focused small molecule drug discovery programs, as well as provide domain area expertise to cross-functional Company initiatives, including development of advanced predictive ADME/PK modeling methodologies and technologies, capability and data growth strategy, and internal/external diligence.

• Work closely with a team of experienced drug hunters to create novel, differentiated drug candidates, by providing strategic guidance and execution associated with in vitro and in vivo profiling, PK/PD/Effect relationship development, and human dose projection to move programs from target concept to the clinic
• Partner closely with a team of AI/ML and data scientists to develop and implement a comprehensive and robust platform for in silico prediction of complex PK/ADME properties
• Together with in vitro ADME leadership, drive a cross-functional strategy aimed at capability refinement and expansion to address growing portfolio needs
• Identify, qualify, engage, and manage external providers of in vitro ADME and in vivo PK services; analyze and interpret resulting data

• Broad DMPK experience and expertise spanning target assessment to the clinic, with an awareness of regulatory guidance and industry trends
• Leading-edge mindset in relation to current experimental and computational DMPK approaches and techniques.  Modeling and simulation expertise preferred  (PBPK and QSP)
• Track record of success rapidly identifying and advancing preclinical development candidates
• Small molecule drug development experience across multiple indications.  Experience in CNS and across multiple modalities a plus
• Ability to effectively communicate and influence in a matrix environment
• Success at sourcing and managing CROs to perform in vitro assays and in vivo studies
• Comfort and productivity in a dynamic, startup environment
• High-performing team mentality, able to lead, follow, and contribute based on the needs of the team and situation
• Ph.D. in a relevant scientific discipline and 10+ years of drug discovery experience or BS/MS and 15+ years

Valo Health, Inc ("Valo") is a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence-driven computation. As a digitally native company, Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company's Opal Computational Platform is an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York. To learn more, visit www.valohealth.com.